Trials / Completed
CompletedNCT00720408
A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.
A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF and Extended Release (XL) Tacrolimus /MMF and Steroid Withdraw in de Novo Liver Transplant Recipients.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF and steroid withdrawal in de novo Liver transplant recipients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prograf-XL | oral |
| DRUG | Prograf | oral |
| DRUG | MMF | oral |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2008-07-22
- Last updated
- 2009-09-15
Locations
4 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00720408. Inclusion in this directory is not an endorsement.